Efficacy of Gushukang granules combined with alendronate sodium in the treatment of diabetic osteoporosis

doi:10.3877/cma.j.issn.2095-8757.2022.03.006

Abstract

Abstract:

Objective

To observe the efficacy of Gushukang granules combined with alendronate sodium in the treatment of diabetic osteoporosis (DOP).

Methods

Eighty patients with DOP admitted to the 903 Hospital of the Chinese PLA Joint Support Force during July 2018 and July 2021 were randomly divided into control group and observation group, with 40 cases in each group. The control group was given alendronate sodium and calcium carbonate D3 tablets, and the observation group was treated with Gushukang in addition. After 6 months of continuous treatment, the visual analogue score (VAS), quality of life Oswestry disability index (ODI) score, the bone mineral density (BMD), the biochemical indexes related to bone metabolism, diabetes control indexes and the occurrence of adverse drug reactions were compared between two groups. Measurement data and count data were compared between groups using t test or χ² test, respectively.

Results

The total effective rate of the observation group was significantly higher than that of the control group (χ²=8.793, P < 0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group (χ²=6.254, P < 0.05). After treatment, the VAS, ODI scores, serum calcium, bone alkaline phosphatase, total typeⅠcollagen amino-terminal prolongating peptide, typeⅠcollagen carboxyl terminal peptide and amino-terminal osteocalcin in the observation group were significantly improved compared with those in the control group (t=7.909, 13.310, 3.535, 3.361, 2.107, 3.211, 5.667; P < 0.05).

Conclusion

Gushukang combined with alendronate sodium is effective and safe for the patients with DOP.

Key words: Gushukang granules, Alendronate sodium, Diabetic osteoporosis, Efficacy, Adverse reaction, Aged

Chun Zhou, Xiang Yu, Mingfeng Fei, Yilian Hong, Yuquan Wu. Efficacy of Gushukang granules combined with alendronate sodium in the treatment of diabetic osteoporosis[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2022, 09(03): 25-28.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2022.03.006

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2022/V09/I03/25

Figures/Tables 3

References 16

[1]	Ramos L, Piedra M, Munoz P, et al. Bone mineral density evolution and incidence of fractures in a cohort of patients with primary hyperparathyroidism treated with parathyroid surgery vs active surveillance during 6 years of follow-up[J]. Endocrinol Diabetes Nutr, 2019, 66(1):41-48.
[2]	夏维波.应重视糖尿病性骨质疏松[J].中华糖尿病杂志，2016，8（1）：1-4.
[3]	Raj JP, Venkatachalam S, Shekoba M, et al. Dietary calcium intake and physical activity levels among people living in Karnataka, India-An observational hospital-based study[J]. J Family Med Prim Care, 2018, 7(6):1411-1416.
[4]	张云，鲁平.老年2型糖尿病患者合并骨质疏松的相关因素分析[J].中华老年医学杂志，2018，37（4）：417-419.
[5]	Zhao Y, Qiu J, Chen T, et al. The efficacy and safety of traditional Chinese medicine's tonifying-kidney, strengthening-spleen, and invigorating-blood circulation (Bushen-Jianpi-Huoxue) principle for type 2 diabetes mellitus with osteoporosis: A protocol for systematic review and meta-analysis[J/OL]. Medicine (Baltimore), 2021, 100(12):e25197.
[6]	Zhang J, Yan B, Chen Z, et al. Risk of new vertebral fracture and combination therapy with zoledronic acid and teriparatide in diabetic patients after percutaneous kyphoplasty[J]. Asian Spine J, 2021, 15(5):611-617.
[7]	Schwartz AV. Efficacy of osteoporosis therapies in diabetic patients[J]. Calcif Tissue Int, 2017, 100(2):165-173.
[8]	苏风兵.中西医治疗糖尿病性骨质疏松的临床观察[J].中国骨质疏松杂志，2020，26（4）：542-545.
[9]	李玉玲.福美加联合消渴壮骨方治疗糖尿病合并骨质疏松的临床研究[J].药物与临床，2013，51（16）：69-71.
[10]	吴多艺，张泰标，李利.温阳补肾法对骨质疏松骨折患者恢复期血清骨钙素、PDGF、SVCAM-1与IGF-1水平影响[J].现代中西医结合杂志，2020，29（1）：67-70.
[11]	Anjaneyulu K, Bhat KM, Srinivasa SR, et al. Beneficial role of hydro-alcoholic seed extract of trigonella foenum graecum on bone structure and strength in menopause induced osteopenia[J]. Ethiop J Health Sci, 2018, 28(6):787-794.
[12]	楚淑芳，赵恒侠，刘德亮，等.糖尿病性骨质疏松的中医药防治[J].世界中医药，2018，13（7）：1804-1808.
[13]	Hauser M, Siegrist M, Keller I, et al. Healing of fractures in osteoporotic bones in mice treated with bisphosphonates—A transcriptome analysis[J]. Bone, 2018, 112:107-119.
[14]	徐海清，黄美琴，袁引芳.骨疏康颗粒联合钙尔奇D片治疗老年性骨质疏松症效果观察[J].中国乡村医药，2016，23（12）：58-59.
[15]	王明熹，蔡慧颜.骨疏康颗粒联合玉龙散外敷治疗原发性骨质疏松症的临床疗效分析[J].海峡药学，2016，28（10）：136-138.
[16]	杨蕾，付勤. 2型糖尿病性骨质疏松骨质量改变研究[J].中华骨质疏松和骨矿盐疾病杂志，2019，12（1）：100-108.

组别	例数	VAS（分）		ODI评分（分）		股骨颈骨密度（g/cm²）		腰椎骨密度（g/cm²）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	6.55±1.38	3.22±1.23	58.34±7.04	13.42±2.38	0.70±0.23	0.81±0.18	0.75±0.21	0.84±0.22
对照组	40	6.46±1.25	5.58±1.27	62.56±7.47	22.53±4.06	0.71±0.22	0.79±0.17	0.75±0.24	0.79±0.18
t值		0.919	7.909	1.400	13.310	1.358	2.500	0.745	2.020
P值		>0.05	<0.05	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

组别	例数	VAS（分）		ODI评分（分）		股骨颈骨密度（g/cm²）		腰椎骨密度（g/cm²）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	6.55±1.38	3.22±1.23	58.34±7.04	13.42±2.38	0.70±0.23	0.81±0.18	0.75±0.21	0.84±0.22
对照组	40	6.46±1.25	5.58±1.27	62.56±7.47	22.53±4.06	0.71±0.22	0.79±0.17	0.75±0.24	0.79±0.18
t值		0.919	7.909	1.400	13.310	1.358	2.500	0.745	2.020
P值		>0.05	<0.05	>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

组别	例数	血清钙（mmol/L）		BAKP（μg/L）		骨钙素（μg/L）		TPⅠNP（ng/ml）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	2.02±0.18	2.18±0.17	10.7±10.5	17.7±7.2	4.7±1.2	5.7±1.2	42.0±9.1	65.8±10.3
对照组	40	2.03±0.20	2.10±0.18	10.6±8.6	16.5±7.8	4.7±1.1	5.6±1.2	43.1±9.7	62.7±12.5
t值		1.239	3.535	0.293	3.361	1.733	0.651	0.926	2.107
P值		>0.05	<0.05	>0.05	<0.05	>0.05	>0.05	>0.05	<0.05
组别	例数	ⅠCTP（ng/L）		N-MID-OT（ng/ml）		25-OHD（ng/ml）		PTH（pg/L）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	0.51±0.15	0.68±0.19	20.3±5.5	17.3±4.1	19.5±8.5	23.3±9.6	54.7±28.1	52.8±25.5
对照组	40	0.48±0.16	0.62±0.17	19.2±5.2	22.0±4.3	18.0±7.7	21.6±8.2	55.0±29.3	54.9±28.6
t值		0.425	3.211	1.453	5.667	0.895	0.374	0.189	1.769
P值		>0.05	<0.05	>0.05	<0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	血清钙（mmol/L）		BAKP（μg/L）		骨钙素（μg/L）		TPⅠNP（ng/ml）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	2.02±0.18	2.18±0.17	10.7±10.5	17.7±7.2	4.7±1.2	5.7±1.2	42.0±9.1	65.8±10.3
对照组	40	2.03±0.20	2.10±0.18	10.6±8.6	16.5±7.8	4.7±1.1	5.6±1.2	43.1±9.7	62.7±12.5
t值		1.239	3.535	0.293	3.361	1.733	0.651	0.926	2.107
P值		>0.05	<0.05	>0.05	<0.05	>0.05	>0.05	>0.05	<0.05
组别	例数	ⅠCTP（ng/L）		N-MID-OT（ng/ml）		25-OHD（ng/ml）		PTH（pg/L）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	0.51±0.15	0.68±0.19	20.3±5.5	17.3±4.1	19.5±8.5	23.3±9.6	54.7±28.1	52.8±25.5
对照组	40	0.48±0.16	0.62±0.17	19.2±5.2	22.0±4.3	18.0±7.7	21.6±8.2	55.0±29.3	54.9±28.6
t值		0.425	3.211	1.453	5.667	0.895	0.374	0.189	1.769
P值		>0.05	<0.05	>0.05	<0.05	>0.05	>0.05	>0.05	>0.05

组别	例数	空腹血糖（mmol/L）		餐后2h血糖（mmol/L）		糖化血红蛋白（%）
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
观察组	40	9.4±1.9	6.2±0.7	13.9±2.3	8.5±1.6	7.5±0.6	6.3±0.5
对照组	40	9.3±1.3	6.4±1.0	13.4±2.5	8.8±1.2	7.5±0.8	6.6±0.4
t值		1.176	0.758	0.414	0.718	0.487	1.731
P值		>0.05	>0.05	>0.05	>0.05	>0.05	>0.05

Please choose a citation manager

Content to export